IGM IMMUNITY TO HIV

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1988
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
7851
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Cellular Products Inc
688 Main St, Buffalo, NY, 14202
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
CONSIDERABLE DATA EXIST WHICH CHARACTERIZE THE HUMAN IGG ANTIBODY RESPONSE TO HUMAN IMMUNODEFICIENCY VIRUS (HIV). INCONTRAST, THE PRESENCE AND PRECISE NATURE OF THE IGM RESPONSE IS LARGELY UNKNOWN. AS FOR PREVIOUSLY DESCRIBED VIRAL IMMUNITIES, THE IGM RESPONSE MAY INDICATE ACUTE EXPOSURE AND/OR INFECTION AND THUS BE AN EARLY EVENT IN THE PATHOGENESIS OF THE DISEASE. THE LONG TERM GOAL OF THIS APPLICATION IS TO PROVIDE STANDARDIZED TECHNOLOGY FOR MEASURMENT OF IGM ANTI-HIV IMMUNITY. THE SPECIFIC AIMS OF THE PRESENT WORK ARE TO INVESTIGATE THOSE PARAMETERS ASSOCIATED WITH THE CONSTRUCTION OF SENSITIVE AND PRECISE IMMUNOASSAYS FOR IGM DETECTION. MURINE MONOCLONAL ANTIBODIES TO HIV SUBCOMPONENTS WILL BE USED AS PROBES TO PRECISELY DEFINE THESPECIFICITY OF THE IGM RESPONSE; THESE INCLUDE CORE PROTEINS, ENVELOPE GLYCOPROTEINS AND REVERSE TRANSCRIPTASE. THE PRE-CLINICAL UTILITY OF IGM ANTI-HIV MONITORING WILL BE INVESTIGATED VERSUS A PANEL OF SERA OBTAINED FROM INDIVIDUALS AT HIGH RISK AND FROM THOSE WITH VARIOUS WALTER-REED STAGES OF HIV INFECTION. HORIZONTAL SPECIMENS OBTAINED PRIOR TO AND DURING ACTIVE SEROCONVERSION WILL BE STUDIED IN ORDER TO DEFINE THE TEMPORAL CHARACTERISTICS OF THE IGM RESPONSE. ALL RESULTS WILL BE COMPARED TO THOSE DATA ACQUIRED FROM THE USE OF IGG ANTIBODY ASSAYS ON THE SAME SPECIMENS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government